Actively Recruiting
Study of Zolbetuximab with Pembrolizumab and Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer
Led by Astellas Pharma Global Development, Inc. · Updated on 2026-10-20
500
Participants Needed
252
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating zolbetuximab combined with pembrolizumab and chemotherapy in adults with stomach cancer or gastroesophageal junction GEJ cancer that is HER2-negative, Claudin 18.2-positive, and PD-L1-positive. The study focuses on people with locally advanced unresectable or metastatic disease who may have had prior standard treatments. This phase 3 randomized, double-blind study aims to understand how well zolbetuximab works with other therapies compared to placebo with pembrolizumab and chemotherapy. Participants receive either zolbetuximab or placebo intravenously every 2 or 3 weeks, along with pembrolizumab infusions every 3 or 6 weeks. Chemotherapy is given as either CAPOX oral capecitabine tablets and oxaliplatin infusions or mFOLFOX6 infusions of oxaliplatin, folinic acid, and 5-fluorouracil over several cycles. Treatment continues until cancer progression, intolerable side effects, or another cancer therapy is needed. Pembrolizumab may be given for up to 2 years. During the study, participants visit clinics for treatment infusions, health checks, and scans to monitor cancer changes. Medical problems and side effects are tracked, and tumor samples may be collected if treatment stops due to progression. Follow-up visits and telephone health checks continue after treatment to monitor participants health and cancer status. The study measures overall survival as the main outcome over up to 72 months.
CONDITIONS
Brief Title
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Research Team
A
Astellas Pharma Global Development Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here